Fig. 1.

Study design. ^aAdalimumab RP 80 mg loading dose on Day 1 and then 40 mg/0.8 mL or 40 mg/0.4 mL EOW from Week 2 to Week 12. ^bFirst PK sampling interval (adalimumab RP only). ^cBI 695501 40 mg/0.8 mL at Week 14 and Week 16, adalimumab RP 40 mg/0.8 mL EOW at Week 18 and Week 20, and then BI 695501 40 mg/0.8 mL EOW from Week 22 to Week 48. ^dAdalimumab RP 40 mg/0.8 mL EOW from Week 14 to Week 48. ^ePrimary endpoints assessment period, and the second PK sampling interval (Week 30–32) in switching (B_T) and continuous (B_R) arms. BSA body surface area, EOW every other week, PASI psoriasis area and severity index, RP reference product, sPGA Static Physician’s Global Assessment